Welcome to our dedicated page for DAVITA SEC filings (Ticker: DVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DaVita Inc. filings document the operating results, governance and capital structure of a public kidney care and dialysis services company. Its 8-K reports furnish quarterly financial results, including revenue, operating income, per-share results, cash flow measures, treatment economics and share repurchase activity.
Proxy filings cover board matters, executive compensation, shareholder voting items and governance disclosures. Other current reports record material financing arrangements, amendments to secured credit facilities, share repurchase authorizations and the company's common stock listing on the New York Stock Exchange under DVA.
Phyllis R. Yale, a director of DaVita Inc. (DVA), reported acquiring 369 shares of DaVita common stock on 08/15/2025 at a reported price of $0. After the reported transaction she beneficially owned 13,570 shares. The Form 4 was filed as an individual filing for one reporting person and was signed by an attorney-in-fact on 08/19/2025.
DaVita Inc. director Barbara J. Desoer, through an attorney-in-fact, reported acquiring 369 shares of DaVita common stock on 08/15/2025 at no cash price indicated on the form and holds 369 shares directly following the transaction. The filing shows she also has indirect beneficial ownership of 12,659 shares through the Marc J. Desoer and Barbara J. Desoer 1998 Trust dated September 7, 1998. The Form 4 was signed by Stephanie N. Berberich as attorney-in-fact on 08/19/2025.
Insider transaction summary: This Form 4 shows that Jason M. Hollar, a director of DaVita Inc. (DVA), acquired 369 shares of DaVita common stock on 08/15/2025. The reported acquisition is coded as A and lists a price of $0, indicating the shares were received without cash payment (e.g., a grant or similar issuance). After the transaction, Mr. Hollar beneficially owned 5,612 shares. The filing was signed by an attorney-in-fact on 08/19/2025.
DaVita Inc. director Gregory J. Moore acquired 369 shares of DaVita common stock on 08/15/2025 at no reported cash price (Code V). After the transaction he beneficially owned 6,820 shares, held directly. The Form 4 discloses this routine insider purchase; no derivative transactions or additional disclosures are reported in the filing.
Wendy L. Schoppert, a director of DaVita Inc. (DVA), reported acquiring 369 shares of DaVita common stock on 08/15/2025 at a reported price of $0. After the transaction she directly owns 369 shares and indirectly owns 2,525 shares through the Wendy L. Schoppert Revocable Trust. The Form 4 was signed by an attorney-in-fact on 08/19/2025. The filing shows a routine insider acquisition by a director and discloses the split between direct and indirect beneficial ownership.
Dennis W. Pullin, a director of DaVita Inc. (DVA), reported an acquisition of 369 shares of DaVita common stock on 08/15/2025 under a non-derivative transaction coded as an acquisition. The filing shows the price per share as $0 and states he beneficially owns 1,678 shares following the transaction, held in a direct capacity.
Form 4 summary: Berkshire Hathaway Inc. and Warren E. Buffett reported an insider sale of DaVita Inc. (DVA) common stock.
Key facts:
- Transaction date: 07/31/2025.
- Sold 1,635,962 shares of Common Stock at $140.6052 per share.
- Amount of securities beneficially owned following the transaction: 32,160,579 (indirect).
- Footnote ownership: 15,528,491 shares held by Government Employees Insurance Company (GEICO), and 16,632,088 shares held by two pension plans (BNSF Master Retirement Trust: 6,100,000; Berkshire Hathaway Inc. Consolidated Pension Plan: 10,532,088).
- Form signed by Warren E. Buffett on 08/04/2025.
DaVita Inc. (DVA) Form 4: Chief Compliance Officer James O. Hearty sold 2,351 common shares on 07/23/2025 at $150.00 each under a pre-arranged Rule 10b5-1 trading plan adopted 03/17/2025. The transaction reduced his direct holdings from an estimated 28,389 to 26,038 shares, a decline of roughly 8.3%. No derivative securities were involved. The filing was signed by an attorney-in-fact on 07/24/2025.
The sale represents a modest portion of the insider’s stake and was executed via an automated plan, which may limit informational value regarding management’s outlook. Investors typically monitor insider activity for sentiment signals, trading-plan usage, and potential supply impacts on the stock’s float.